Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.
Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $127
Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $132 to $127.
HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $35 price target.
HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $27 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $27 price target.
HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $140 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $140 price target.
HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $4 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $4 price target.
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price target.
HC Wainwright & Co. Reiterates Buy on Actinium Pharmaceuticals, Maintains $53 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharmaceuticals (AMEX:ATNM) with a Buy and maintains $53 price target.
HC Wainwright & Co. Reiterates Buy on Atreca, Maintains $25 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Atreca (NASDAQ:BCEL) with a Buy and maintains $25 price target.